169 related articles for article (PubMed ID: 28820285)
21. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
Yeung R; Hamm J; Liu M; Schellenberg D
Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.
Mesko S; Sandler K; Cohen J; Konecny G; Steinberg M; Kamrava M
Int J Gynecol Cancer; 2017 Feb; 27(2):403-408. PubMed ID: 27870704
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
Lazzari R; Ronchi S; Gandini S; Surgo A; Volpe S; Piperno G; Comi S; Pansini F; Fodor C; Orecchia R; Tomao F; Parma G; Colombo N; Jereczek-Fossa BA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):650-660. PubMed ID: 29893277
[TBL] [Abstract][Full Text] [Related]
25. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
26. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
27. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
Ost P; Jereczek-Fossa BA; As NV; Zilli T; Muacevic A; Olivier K; Henderson D; Casamassima F; Orecchia R; Surgo A; Brown L; Tree A; Miralbell R; De Meerleer G
Eur Urol; 2016 Jan; 69(1):9-12. PubMed ID: 26189689
[TBL] [Abstract][Full Text] [Related]
28. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
29. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).
Wong AC; Watson SP; Pitroda SP; Son CH; Das LC; Stack ME; Uppal A; Oshima G; Khodarev NN; Salama JK; Weichselbaum RR; Chmura SJ
Cancer; 2016 Jul; 122(14):2242-50. PubMed ID: 27206146
[TBL] [Abstract][Full Text] [Related]
30. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study.
Burkon P; Kazda T; Pospisil P; Slavik M; Kominek L; Selingerova I; Blakaj DM; Prochazka T; Vrzal M; Rehak Z; Slampa P
Neoplasma; 2019 Mar; 66(2):315-325. PubMed ID: 30509112
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy of bone metastases in oligometastatic disease: prognostic factors of oncologic outcomes.
Ursino S; Montrone S; Cantarella M; Menghini V; Matteucci F; Mazzotti V; Fiorica F; Fedele D; Erba P; Morganti R; Fabrini MG; Caramella D
Tumori; 2016; 102(1):59-64. PubMed ID: 26439149
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
Barney BM; Olivier KR; Macdonald OK; Fong de Los Santos LE; Miller RC; Haddock MG
Am J Clin Oncol; 2012 Dec; 35(6):537-42. PubMed ID: 21659830
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
35. Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.
Sutera P; Clump DA; Kalash R; D'Ambrosio D; Mihai A; Wang H; Petro DP; Burton SA; Heron DE
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):116-122. PubMed ID: 30149056
[TBL] [Abstract][Full Text] [Related]
36. Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?
Augugliaro M; Marvaso G; Ciardo D; Zerini D; Riva G; Rondi E; Vigorito S; Comi S; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Neoplasma; 2019 Jan; 66(1):160-165. PubMed ID: 30509099
[TBL] [Abstract][Full Text] [Related]
37. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer.
Jereczek-Fossa BA; Piperno G; Ronchi S; Catalano G; Fodor C; Cambria R; Fossati Ing P; Gherardi F; Alterio D; Zerini D; Garibaldi C; Baroni G; De Cobelli O; Orecchia R
Am J Clin Oncol; 2014 Jun; 37(3):227-33. PubMed ID: 22992626
[TBL] [Abstract][Full Text] [Related]
38. Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT).
García-Cabezas S; Bueno C; Rivin E; Roldán JM; Palacios-Eito A
Clin Transl Oncol; 2015 Aug; 17(8):668-72. PubMed ID: 26022130
[TBL] [Abstract][Full Text] [Related]
39. The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly.
Scorsetti M; Clerici E; Navarria P; D'Agostino G; Piergallini L; De Rose F; Ascolese A; Tozzi A; Iftode C; Villa E; Comito T; Franzese C; Mancosu P; Tomatis S; Cozzi L
Br J Radiol; 2015 Sep; 88(1053):20150111. PubMed ID: 26183933
[TBL] [Abstract][Full Text] [Related]
40. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
